Shock as UK drops down global women's health league for fourth year in a row
UK WOMEN FAILED Shock as UK drops down global women's health league for fourth year in a row
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
THE UK has dropped down a global women's health league for the fourth year in a row.
Countries such as Kosovo, Kazakhstan and Saudi Arabia ranked better.
Sign up for Scottish Sun
newsletter
Sign up
British women are more likely to experience poor emotional health and chronic pain than the EU average, it was revealed.
The UK — the sixth richest nation in the world — ranks 41st out of 142 in the Hologic Global Women's Health Index.
That is down from 37 last year and 30 in 2023.
The annual league is based on polls of more than 78,000 women globally.
It showed maternity care quality has declined and women here are less likely than in similar nations to be checked for conditions such as high blood pressure, diabetes and cancer.
British women also report higher rates of sadness, stress and anger than five years ago.
Tim Simpson, of health tech firm Hologic, said: 'This is a four-year decline that no one can ignore.'
Janet Lindsay, boss of charity Wellbeing of Women, said: 'These figures are unacceptable for one of the world's wealthier nations. They reflect long- standing under-investment.'
The report scores countries out of 100 based on women's responses on issues such as illness, personal safety, medical care and mental health.
Top of the table was Taiwan (68) and Kuwait (67).
Millions of women live life according to their menstrual cycle, study shows
The UK scored 59, behind USA (60), Kazakhstan (63), Saudi Arabia (63) and Kosovo (60).
We placed 23rd out of 31 in Europe.
The Department of Health said: 'We're on a mission to get the NHS working for women. Equality will be at the heart of our Ten-Year Health Plan.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
27 minutes ago
- Scottish Sun
Rival fat jab WON'T increase in price, makers pledge – as Mounjaro set to double in costs
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) MAKERS of the fat jab Wegovy say they will not increase the price of the drug when the cost of rival Mounjaro doubles next month. A price war now looms as Danish firm Novo Nordisk said it is committed to keeping its weight loss injection affordable. Sign up for Scottish Sun newsletter Sign up 1 Wegovy is one of the two most popular weight loss injections in the UK (stock image) Credit: Reuters Slimmers suffered a hammer blow on Thursday when Mounjaro maker Eli Lilly & Co revealed it would ramp up its pharmacy charges in September. Rates first revealed by The Sun show the UK wholesale price for a month's supply of the popular 5mg dose of tirzepatide will double from £92 to £180. A prescription with private pharmacy mark-ups typically costs buyers £150 to £200 and could now surge to more than £300. The minimum 2.5mg dose will cost pharmacies £133 up from £92, with a 10mg dose rising from £107 to £255 and the maximum 15mg from £122 to £330. Patients and pharmacists were shocked by the news and warned it could drive users to the black market. Price war could shake up market Wegovy is thought to be the second most popular weight loss injection used in the UK. It could now see a boom in users as its price will become more competitive after Mounjaro's rise. Studies suggest the jab, known as semaglutide and the same as Ozempic, is not as strong as Mounjaro but is still super-effective. Wegovy currently costs between £100 and £200 per month from private online pharmacies. A Novo Nordisk spokesperson told The Sun: 'We currently have no plans of changing our offering in the UK. 'Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most. 'Our mission is to help create a healthier world by addressing some of the most pressing threats to public health – including obesity, diabetes, and cardiovascular disease.'
Spectator
2 hours ago
- Spectator
Mounjaro won't be the last drug company to bow to Trump
If you need to lose a few pounds after enjoying the French or Italian food a little too much on your summer holiday, there might soon be a problem. The cost of one of the new weight loss drugs that has become so popular in recent months is about to get a lot more expensive. The American drugs giant Eli Lilly doubling the price of Mounjaro in the UK. The price of one diet pill does not make a great deal of difference. The trouble is, the decision was prompted by President Trump's determination to make the cost of medicines a lot fairer between the United States and the rest of the world. This is going to end up costing Britain, along with many other countries, a lot of money. Eli Lilly will be increasing the British price of Mounjaro, the most popular and effective weight loss injection, from £92 for a medium-sized dose to £180, and from £122 to £330 for a stronger version. The reason is simple. President Trump, with his typically blunt language, complained about how a friend of his brought 'the fat drug' in London at a far lower price than in the US despite being 'the same box made in the same plant by the same company'. More broadly, President Trump has made a big issue of the huge differences in drug prices between the US and other countries. He has imposed tariffs that could go as high as 250 per cent to force the major pharmaceutical companies to bring their manufacturing onshore and lower prices for American patients. Eli Lilly's response, quite rationally, has been to increase the price in the UK to start to close the gap and keep the President happy. Eli Lilly won't be the last pharmaceutical company to do this. Truth be told, President Trump has a point about the unfairness of drug prices in his country. On average, medicines cost 2.7 times more in the US than they do in the rest of the world. That might make sense for poor countries, but it is hard to see why developed economies in Europe, the Gulf or Asia should pay so much less for medicines than America does. In effect, the US subsidises the rest of the world, paying for the huge cost of research while the rest of the world gets drugs at far less than they would otherwise cost. But if that is rebalanced, medicines will inevitably get a lot more expensive, both for private patients and in time for the NHS as well. Given that the UK spends £34 billion a year on pharmaceuticals and that £19 billion of that comes from the NHS, that is going to be a very big bill – and one that we can barely afford.
Scottish Sun
2 hours ago
- Scottish Sun
Warning as deadly ‘suitcase viruses' that destroy organs and trigger brain swelling spread across the UK and Europe
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) DEADLY viruses could be making their way to the UK on planes and in holidaymakers' suitcases, experts warn. They say international travel is fuelling a "concerning" rise in both chikungunya and oropouche, and the worst could be yet to come. Sign up for Scottish Sun newsletter Sign up 18 Mosquitoes carrying potentially-deadly viruses could be making their way to the UK on planes Credit: Getty 18 There have been outbreaks of chikungunya and oropouche in countries like China, Brazil and Mauritius Credit: Getty 18 Lockdown measures and insecticide sprays are in force in some areas Credit: Reuters It comes against a backdrop of growing chikungunya outbreaks across the world, including a surge in cases in the UK. And the first case of oropouche has been detected in the UK, in travellers from Brazil. Simon Clarke, professor of cellular microbiology at the University of Reading, told The Sun: "As Brits develop more exotic tastes for travel to warmer places closer to the equator, we are increasingly likely to see unusual infections upon their return. "While oropouche is mainly found in the Amazon and chikungunya in sub-tropical regions, they are spreading. "Both have been detected in the United States and Europe, where sporadic outbreaks in France and Italy have occurred." Paul Hunter, a professor of medicine at the University of East Anglia, added: "There is a small risk of airport associated infections whereby infected mosquitoes arrive in the UK on board airplanes and then escape. "The spread of any infection into a previously unexposed population is always a matter for concern." Chikungunya is a virus spread by mosquito bites, the symptoms of which include a sudden fever and joint pain. Most people recover within two weeks, but the joint pain can last for months or even years, according to the UK Health Security Agency (UKHSA). In some cases, it is so bad it causes sufferers to "fold in half" or "become contorted" as they double over in agony. Serious complications are not common, but in rare cases the disease can cause organ damage and be fatal, particularly in very young or older people, or those with underlying health conditions. Oropouche virus There have been 73 cases of chikungunya reported in England, primarily in London, between January and June 2025 - the highest number ever recorded. This compares to 27 cases for the same period last year, according to data from the UK Health and Security Agency. The majority were linked to travel to Sri Lanka, India and Mauritius. There is currently no risk of onward transmission of chikungunya, as the two species of mosquito that transmit the disease are not established in the UK. But Prof Hunter says: "The fact that locally-acquired infections are being reported from multiple locations this year is concerning. "There will be several more weeks before the mosquito season starts to tail off [so it could get worse]. "We will almost certainly see more cases in the UK, but at least for a few decades, these are all likely to have been acquired overseas. "Both chikungunya and oropouche can occasionally be fatal." Experts fear cases could rise due to global travel and rising temperatures. Prof Clarke said: "Chikungunya is spread by mosquitoes, one of which, the tiger mosquito, has been detected in the South East of England. 18 "It's worth emphasising the negative impact that global warming may have on a resilience to infections like this, which we've always taken for granted in the UK. "A warmer climate may mean that we have to take greater precautions at home against infections spread by insects." Prof Hunter added: "We have seen local outbreaks of both dengue and chikungunya multiple times on the Mediterranean coasts of France, Italy and Spain over the past decade, and such events seem to be becoming more frequent. "Chikungunya outbreaks are less common than dengue, but when we do see them, they tend to be big, at least in Italy." Chikungunya can be a nasty disease and we're seeing a worrying increase in cases among travellers returning to the UK Dr Philip Veal Chikungunya mainly occurs in Africa and southern Asia, although cases have been reported in Europe and parts of North America. This year, there have been outbreaks in the Americas and Asia, with surges on the Indian Ocean islands of Reunion, Mayotte and Mauritius. More than 10,000 people have also been struck down in China since June 2025. The majority of cases have been reported in Foshan, a city in the southern Guangdong province, where officials have since rolled out Covid-style lockdowns and been spraying insecticides in a desperate bid to stop the virus from spiralling out of control. At least 12 other cities in the southern Guangdong province have also reported infections, as well as Hong Kong and Taiwan. Since early 2025, there have been 240,000 cases and 90 deaths reported in 16 countries, according to the European Centre for Disease Prevention and Control (ECDC). 18 A patient with joint deformities after contracting chikungunya Credit: SehatHub 18 A doctor treats a chikungunya patient on Reunion island Credit: AFP 18 A staff member carries out mosquito eradication work in Changsha, China, in August 2025 Credit: Getty 18 A worker sprays insecticide at a residential community in Foshan, China Credit: Getty Two chikungunya vaccines are approved for use in the UK and are available to buy after an assessment at a private travel clinic. Travellers can stay safe by using insect repellent and covering their skin, especially at dawn and dusk. 'ESSENTIAL' PRECAUTIONS Dr Philip Veal, consultant in public health at UKHSA, said: "Chikungunya can be a nasty disease and we're seeing a worrying increase in cases among travellers returning to the UK. "While this mosquito-borne infection is rarely fatal, it can cause severe joint and muscle pain, headaches, sensitivity to light and skin rashes. "Thankfully symptoms usually improve within a few weeks, but joint pain may last for months or longer. "It is essential to take precautions against mosquito bites when travelling. "Simple steps, such as using insect repellent, covering up your skin and sleeping under insecticide-treated bed nets can greatly reduce the risk." 18 The UKHSA has also detected the first cases of oropouche in travellers coming to the UK from Brazil. The flu-like illness can cause a fever, headaches, joint pain, muscle pain, chills, nausea and vomiting. In serious cases, it can cause brain-swelling, specifically in the form of encephalitis and meningitis. Officials are urging anyone who becomes unwell after travel to affected areas, including parts of Central and South America and the Caribbean, to seek urgent medical advice. According to the World Health Organisation (WHO), before late 2023, oropouche was mostly reported near the Amazon rainforest area. It was dubbed 'sloth fever' as it circulates between primates, sloths and birds before occasionally being passed to humans by midges and mosquitoes. In 2024, Brazil, Bolivia, Colombia, Cuba, Guyana, Peru and the Dominican Republic reported locally transmitted cases of the disease. Travel-related cases are now cropping up across Europe. 18 Francois Balloux, professor of computational systems biology and director of the UCL Genetics Institute, specialising in infectious diseases, said: "There seems to have been a marked increase of both chikungunya and oropouche cases in the parts of the world where they're endemic. "It is obviously a problem as both are unpleasant viruses. "Neither could circulate in the UK as their vectors are absent, but travellers are being infected overseas and returning home. "The number of cases in the UK could go up or down in the future." 18 Insecticide fog in Colombo, Sri Lanka, to try to combat rising chikungunya cases Credit: AFP 18 Patients with chikungunya being treated in Reunion Credit: AFP 18 Insecticide being poured into a drone amid a city-wide clean-up in Guangzhou, China Credit: Getty 18 A woman covers her face from insecticide fog amid a chikungunya outbreak in Colombo, Sri Lanka Credit: AFP The first imported cases of oropouche were reported in Europe in June and July 2024. There were 12 in Spain, five in Italy and two in Germany. All had a history of travel to Cuba or Brazil. Direct human-to-human transmission of the virus has not been documented so far, according to the ECDC. The prognosis for recovery is good and "fatal outcomes are extremely rare". There are no vaccines to prevent or specific medication to treat oropouche. The UKHSA report also shows a rise in travel-associated cholera cases in the UK, with eight cases in the first half of the year compared to just one in 2024. Most cases were linked with travel to India and Ethiopia. There was also a 67 per cent decrease in the number of dengue cases reported in England, Wales and Northern Ireland from January to June, and there were just four cases of zika virus during the period, down from nine in 2024. Oropouche virus: Everything you need to know Oropouche is a disease caused by Oropouche virus. It is spread through the bites of infected midges (small flies) and mosquitoes. Symptoms ARE similar to dengue and include: a headache, fever, muscle aches, stiff joints, nausea, vomiting, chills, or sensitivity to light. Severe cases may result in brain diseases such as meningitis. Symptoms typically start four to eight days after being bitten and last three to six days. Most people recover without long-term effects. There are no specific medications or vaccines available. Travellers heading to affected areas should take steps to avoid bug bites. The virus is endemic in many South American countries, in both rural and urban communities. Outbreaks are periodically reported in Brazil, Bolivia, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. Wear tops with long sleeves and long trousers, apply insect repellent regularly, and sleep under a mosquito net if you are not in enclosed, air-conditioned accommodation. Source: US Centre for Disease Control and Prevention 18 A laboratory technician doing screening tests during the chikungunya epidemic in Reunion Credit: AFP 18 A health worker fumigates against disease-carrying mosquitoes in Contagem, Brazil Credit: AFP 18 France's President Emmanuel Macron visiting French military fighting against chikungunya in Reunion Credit: AFP 18 More fumigation efforts in Contagem, Brazil Credit: AFP
